Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7X2O

Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 2E6 (CVB1-M:2E6)

Summary for 7X2O
Entry DOI10.2210/pdb7x2o/pdb
EMDB information32969
DescriptorVirion protein 1, VP2, VP3, ... (7 entities in total)
Functional Keywordscoxsackievirus b1, neutralizing antiboy, cryo-em, virus
Biological sourceCoxsackievirus B1
More
Total number of polymer chains6
Total formula weight119210.88
Authors
Zheng, Q.,Zhu, R.,Sun, H.,Cheng, T.,Li, S.,Xia, N. (deposition date: 2022-02-25, release date: 2022-09-28, Last modification date: 2025-06-18)
Primary citationZheng, Q.,Zhu, R.,Yin, Z.,Xu, L.,Sun, H.,Yu, H.,Wu, Y.,Jiang, Y.,Huang, Q.,Huang, Y.,Zhang, D.,Liu, L.,Yang, H.,He, M.,Zhou, Z.,Jiang, Y.,Chen, Z.,Zhao, H.,Que, Y.,Kong, Z.,Zhou, L.,Li, T.,Zhang, J.,Luo, W.,Gu, Y.,Cheng, T.,Li, S.,Xia, N.
Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail.
Cell Host Microbe, 30:1279-, 2022
Cited by
PubMed Abstract: Coxsackievirus B1 (CVB1) is an emerging pathogen associated with severe neonatal diseases including aseptic meningitis, myocarditis, and pancreatitis and also with the development of type 1 diabetes. We characterize the binding and therapeutic efficacies of three CVB1-specific neutralizing antibodies (nAbs) identified for their ability to inhibit host receptor engagement. High-resolution cryo-EM structures showed that these antibodies recognize different epitopes but with an overlapping region in the capsid VP2 protein and specifically the highly variable EF loop. Moreover, they perturb capsid-receptor interactions by binding various viral particle forms. Antibody combinations achieve synergetic neutralization via a stepwise capsid transition and virion disruption, indicating dynamic changes in the virion in response to multiple nAbs targeting the receptor-binding site. Furthermore, this three-antibody cocktail protects against lethal challenge in neonatal mice and limits pancreatitis and viral replication in a non-obese diabetic mouse model. These results illustrate the utility of nAbs for rational design of therapeutics against picornaviruses such as CVB.
PubMed: 36002016
DOI: 10.1016/j.chom.2022.08.001
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.15 Å)
Structure validation

238895

PDB entries from 2025-07-16

PDB statisticsPDBj update infoContact PDBjnumon